A Corrigendum on
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
by Lu, D.-S., Chen, C., Zheng, Y.-X., Li, D.-D., Wang, G.-Q., Liu, J., et al. (2018). Front. Mol. Neurosci. 11:155. doi: 10.3389/fnmol.2018.00155
In the original article, there was a mistake in Figure 6 as published. One western blot band of β-actin corresponding to TNF-α protein level 21 days after daily L-DOPA combined with ICA treatment in Figure 6B was inserted incorrectly. The corrected Figure 6 appears below.
FIGURE 6
Figure 6. ICA inhibited the neuroinflammation in LID after 6-OHDA-induced DA neuronal damage. The protein levels of neuroinflammatory factors, such as COX-2, IL-1[beta] and TNF-[alpha], in the SN were detected 7 (A) and 21 (B) days after daily L-DOPA (25 mg/kg, i.p.) combined with ICA (20 mg/kg, p.o.) treatment by western blotting. Data were shown as mean ± SEM from six rats (n = 6). *p < 0.05 compared with the control group; #p < 0.05 compared with 6-OHDA-treated group; Ψp < 0.05 compared with 6-OHDA+L-DOPA group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Di-Sheng Lu†, Ce Chen†, Ya-Xin Zheng†, Dai-Di Li, Guo-Qing Wang, Jie Liu, Jingshan Shi and Feng Zhang*
* Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.